Cargando…

Evaluation of the Prognostic Value of Low-Frequency KRAS Mutation Detection in Circulating Tumor DNA of Patients with Metastatic Colorectal Cancer

KRAS mutation in tumor tissue is a well-known predictor of resistance to the treatment of anti-EGFR antibodies in metastatic colorectal cancers (mCRC). However, the prognostic value of low-frequency plasma circulating tumor DNA (ctDNA) KRAS mutation in predicting treatment resistance in pretreated m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lin, Chien-Yu, Shen, Ming-Yin, Chen, William Tzu-Liang, Yang, Chin-An
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10381461/ https://www.ncbi.nlm.nih.gov/pubmed/37511664 http://dx.doi.org/10.3390/jpm13071051

Ejemplares similares

Prognostic and predictive value of KRAS mutation number in metastatic colorectal cancer
por: Ucar, Gokhan, et al.
Publicado: (2020)

The prognostic values of EGFR expression and KRAS mutation in patients with synchronous or metachronous metastatic colorectal cancer
por: Huang, Ching-Wen, et al.
Publicado: (2013)

Mutations matter: An observational study of the prognostic and predictive value of KRAS mutations in metastatic colorectal cancer
por: Lavacchi, Daniele, et al.
Publicado: (2022)

Prognostic Value of KRAS Mutations in Colorectal Cancer Patients
por: Koulouridi, Asimina, et al.
Publicado: (2022)

The predictive value of KRAS and NRAS mutations in metastatic colorectal cancer
por: Eshraghi, Abbas, et al.
Publicado: (2020)

Prognostic Value of Autophagy, Microsatellite Instability, and KRAS Mutations in Colorectal Cancer
por: Wang, Yuanyuan, et al.
Publicado: (2021)

Low value of detection of KRAS2 mutations in circulating DNA to differentiate chronic pancreatitis to pancreatic cancer
por: Marchese, R, et al.
Publicado: (2004)

Prognostic value of absolute quantification of mutated KRAS in circulating tumour DNA in lung adenocarcinoma patients prior to therapy
por: Wahl, Sissel Gyrid Freim, et al.
Publicado: (2021)

Diagnostic and Prognostic Values of KRAS Mutations on EUS-FNA Specimens and Circulating Tumor DNA in Patients With Pancreatic Cancer
por: Wang, Ronghua, et al.
Publicado: (2022)

Context-dependent interpretation of the prognostic value of BRAF and KRAS mutations in colorectal cancer
por: Popovici, Vlad, et al.
Publicado: (2013)

KRAS mutation analysis of single circulating tumor cells from patients with metastatic colorectal cancer
por: Kondo, Yuurin, et al.
Publicado: (2017)

The Frequency of Specific KRAS Mutations, and Their Impact on Treatment Choice and Survival, in Patients With Metastatic Colorectal Cancer
por: Fernández Montes, Ana, et al.
Publicado: (2023)

KRAS-mutation incidence and prognostic value are metastatic site-specific in lung adenocarcinoma: poor prognosis in patients with KRAS mutation and bone metastasis
por: Lohinai, Zoltan, et al.
Publicado: (2017)

Early changes in circulating tumor DNA (ctDNA) predict treatment response in metastatic KRAS-mutated colorectal cancer (mCRC) patients
por: Lavacchi, Daniele, et al.
Publicado: (2023)

Prognostic value of circulating endothelial cells in metastatic colorectal cancer
por: Rahbari, Nuh N, et al.
Publicado: (2017)

KRAS mutational status analysis of peripheral blood isolated circulating tumor cells in metastatic colorectal patients
por: GUTIÉRREZ, CRISTINA, et al.
Publicado: (2013)

The Prognostic Value of (18)F-FDG PET/CT and KRAS Mutation in Colorectal Cancers
por: Arslan, Esra, et al.
Publicado: (2020)

Prognostic Value of KRAS Gene Mutation on Survival of Patients with Peritoneal Metastases of Colorectal Adenocarcinoma
por: Díez-Alonso, Manuel, et al.
Publicado: (2021)

Prognostic Value of KRAS Exon 3 and Exon 4 Mutations in Colorectal Cancer Patients
por: Guo, Tianan, et al.
Publicado: (2021)

Monitoring circulating tumor DNA revealed dynamic changes in KRAS status in patients with metastatic colorectal cancer
por: Takayama, Yuji, et al.
Publicado: (2018)

Treatment monitoring in metastatic colorectal cancer patients by quantification and KRAS genotyping of circulating cell-free DNA
por: Berger, Andreas W., et al.
Publicado: (2017)

Prognostic and Predictive Roles of KRAS Mutation in Colorectal Cancer
por: Arrington, Amanda K., et al.
Publicado: (2012)

KRAS mutational concordance between primary and metastatic colorectal adenocarcinoma
por: PALIOGIANNIS, PANAGIOTIS, et al.
Publicado: (2014)

KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer
por: Spindler, K G, et al.
Publicado: (2013)

Mutations of KRAS/NRAS/BRAF predict cetuximab resistance in metastatic colorectal cancer patients
por: Hsu, Hung-Chih, et al.
Publicado: (2016)

Clinical Characteristics of Metastatic Colorectal Cancer Combined with Gastrointestinal Perforation and Prognostic Value of Circulating Tumor DNA
por: Yang, Hong, et al.
Publicado: (2022)

Utility of KRAS mutation detection using circulating cell‐free DNA from patients with colorectal cancer
por: Yamada, Takeshi, et al.
Publicado: (2016)

Preoperative detection of KRAS mutated circulating tumor DNA is an independent risk factor for recurrence in colorectal cancer
por: Nakamura, Yuki, et al.
Publicado: (2021)

Prognostic role of KRAS mutations in Sardinian patients with colorectal carcinoma
por: Palomba, Grazia, et al.
Publicado: (2016)

Clinical-Pathological Correlation of KRAS Mutation Status in Metastatic Colorectal Adenocarcinoma
por: Ribeiro, Karen Bento, et al.
Publicado: (2013)

KRAS Mutation Status in Bulgarian Patients with Advanced and Metastatic Colorectal Cancer
por: Radanova, Maria, et al.
Publicado: (2023)

Comment on ‘KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer'
por: Tougeron, D, et al.
Publicado: (2014)

KRAS and NRAS mutation detection in circulating DNA from patients with metastatic colorectal cancer using BEAMing assay: Concordance with standard biopsy and clinical evaluation
por: Lastraioli, Elena, et al.
Publicado: (2021)

The prognostic value of KRAS mutation by cell-free DNA in cancer patients: A systematic review and meta-analysis
por: Zhuang, Rongyuan, et al.
Publicado: (2017)

KRAS p.G12C Mutation in Metastatic Colorectal Cancer: Prognostic Implications and Advancements in Targeted Therapies
por: Ottaiano, Alessandro, et al.
Publicado: (2023)

Extreme assay sensitivity in molecular diagnostics further unveils intratumour heterogeneity in metastatic colorectal cancer as well as artifactual low-frequency mutations in the KRAS gene
por: Mariani, Sara, et al.
Publicado: (2017)

Fragment Enrichment of Circulating Tumor DNA With Low-Frequency Mutations
por: Liu, Xiaojun, et al.
Publicado: (2020)

Prognostic and predictive value of TOPK stratified by KRAS and BRAF gene alterations in sporadic, hereditary and metastatic colorectal cancer patients
por: Zlobec, I, et al.
Publicado: (2010)

The diagnostic accuracy of circulating free DNA for the detection of KRAS mutation status in colorectal cancer: A meta‐analysis
por: Xie, Wenli, et al.
Publicado: (2019)

Effectiveness of circulating tumor DNA for detection of KRAS gene mutations in colorectal cancer patients: a meta-analysis
por: Hao, Yi-Xin, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_jtt971j3o0lpjl6qi8611vn1l0